Consumer Health Cancer / Immunology
Lunit, a global leader in AI-powered cancer diagnostics, has announced groundbreaking results from the world’s first large-scale, multicenter, prospe...
March 11, 2025 | News
The first patient has been dosed with EVM16 at Peking University Cancer Hospital, marking a major milestone as Everest's proprietary AI-based tumor neoan...
March 07, 2025 | News
Phase Ib trial to evaluate CS5001 in combination with R-CHOP as a first-line treatment for diffuse large B-cell lymphoma (DLBCL), aiming to reshape ...
March 06, 2025 | News
CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therap...
March 05, 2025 | News
Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) ENHERTU® (trastuzumab deruxtecan) has been recommended for approval in th...
March 03, 2025 | News
Fapon Biopharma, a biotech innovator in developing therapeutic antibodies and fusion proteins, is pleased to announce that the U.S. Food and Drug Administr...
March 03, 2025 | News
Akeso, Inc. (9926.HK) announced the first patient has been enrolled in the Phase I clinical trial of AK138 D1 for the treatment of advanced malignancies in...
February 28, 2025 | News
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced the company has successfully enrolled the first patient in its multicenter, ran...
February 24, 2025 | News
Harbour BioMed, a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on...
February 21, 2025 | News
Syensqo, a leading specialty chemicals company, is pleased to announce a strategic partnership with Emulseo, a French company specialized in formulations f...
February 21, 2025 | News
Out-licenses BxC-I17e, Exosome-Based Therapeutics for New IndicationsKRW 3 Billion Non-Refundable Upfront Payment + Milestone Payments + Double-Digit ...
February 20, 2025 | News
Bambusa Therapeutics, Inc. (Bambusa), a biotechnology company developing bispecific antibodies for immunological and inflammatory (I&I) disorders, anno...
February 17, 2025 | News
Alphamab Oncology announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-306) of anti-HER2 biparat...
February 14, 2025 | News
Lion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance from the U.S. Food and Drug A...
February 12, 2025 | News
Most Read
Bio Jobs
News
Editor Picks